Henry Kaplan from University of Louisville School of Medicine: Combatting Retinal Degeneration with Glucose

Video

According to Henry Kaplan, MD, University of Louisville School of Medicine, "One has to recognize that there are multiple approaches like gene therapy, neuroprotection, stem cell transplantation, and pharmacologic manipulation of other genes really holds the greatest benefit in terms of trying to reverse the inevitable loss of vision."

At the ARVO 2016 meeting in Seattle, WA, Henry Kaplan, MD, University of Louisville School of Medicine, discussed how access to glucose that would normally be transplanted to the subretinal space for metabolism could aid in restoring normal rod function in retinal degeneration.

"One has to recognize that there are multiple approaches like gene therapy, neuroprotection, stem cell transplantation, and pharmacologic manipulation of other genes really holds the greatest benefit in terms of trying to reverse the inevitable loss of vision," Kaplan commented.

Recent Videos
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Steven W. Pipe, MD, a professor of pediatric hematology/oncology at CS Mott Children’s Hospital
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Related Content
© 2025 MJH Life Sciences

All rights reserved.